Linking serum malondialdehyde with dyslipidemia in patients with metabolic syndrome.

Dyslipidemia and obesity is becoming an increasingly serious public health issue. Therefore, it is of interest to determine the serum levels of malondialdehyde (MDA) with dyslipidemia in patients with metabolic syndrome. The routine demographic, anthropometric and the biochemical parameters analyzed. Additionally, the degree of lipid peroxidation was measured by serum levels of malondialdehyde (MDA). The body mass index, systolic and diastolic blood pressure, fasting blood sugars, lipid profile significantly elevated in metabolic syndrome patients when compared to healthy controls. The serum MDA levels significantly elevated and correlated positively with abdominal hyperglycemia, hypertension, obesity and negatively with HDL (p=0.0001**). Thus, the early detection of people at risk for getting metabolic syndrome can be improved by measuring the MDA biomarker.